An Official Website of the United States Government
Treatment of Sepsis with Talactoferrin
- Small Business Information
-
Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: Yes
- Phase 2
-
Fiscal Year: 2008Title: Treatment of Sepsis with TalactoferrinAgency: HHSContract: 4R44GM077816-02Award Amount: $2,462,044.00
Abstract:
DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring e very year. This means that in the United States, more than 500 patients die from severe sepsis every day, with 28% to 50% of the patients succumbing to the disease process at an average cost of 22,000 per patient. Successful development of TLF-based thera py for sepsis would satisfy a significant unmet medical need. Agennix has now established a manufacture of a pharmaceutical-grade talactoferrin, it has demonstrated its safety in clinical studies for various indications, and is now interacting with the FDA to obtain a go-ahead to initiate clinical Phase 3 studies in cancer. The development of talactoferrin is therefore at a stage that a demonstration of its clinical efficacy in sepsis would put the generation of a product to treat sepsis on a relatively eas y and straightforward path.Small Business Information at Submission:AGENNIX, INC.
AGENNIX, INC. 8 GREENWAY PLZ, STE 910 HOUSTON, TX 77046EIN/Tax ID: 954405779DUNS: N/ANumber of Employees: N/AWoman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
Award Information
|
Agency: Department of Health and Human Services |
Branch: N/A |
Award ID: 88640 |
Program Year/Program: 2008 / SBIR |
|
Agency Tracking Number: GM077816 |
Solicitation Year: N/A |
Solicitation Topic Code: N/A |
Solicitation Number: N/A |